A. Rossi, P. Stratta, L. Arduini - Vol. 8, December 2002, Issue 4
Testo Immagini Bibliografia Summary Indice
La compliance al trattamento farmacologico
con antipsicotici
Compliance with antipsychotic medication
1 Blackwell B. Compliance. Psychother Psychosom 1992;58:161-9.
2 Bebbington PI. The content and context of compliance. Int Clin Psychopharmacol 1995;9:41-50.
3 Awad AG, Voruganti L, Heslegrave RJ, Hogan TP. Assessment of the patient’s subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996;11:55-9.
4 Kampman O, Lehtinen K. Compliance in psychoses. Acta Psychiatr Scand 1999;100:167-75.
5 Lindström E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Pharmacoeconomics 2000;18:105-24.
6 Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Comm Psychiatry 1990;41:1203-11.
7 Rossi A, Bustini M. La gestione del paziente in trattamento con antipsicotici: obiettivi terapeutici, compliance e tollerabilità. Rivista di Psichiatria 1998;33:13-9.
8 Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand 2000;102:83-6.
9 Caron HS, Roth HP. Patients’ cooperation with a medical regimen. J Am Med Ass 1968;203:922-6.
10 Babiker IE. Non-compliance in schizophrenia. Psychiatr Develop 1986;4:329-37.
11 Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995;49:321-7.
12 Young MS. Strategies for improving compliance. Clin Nurs 1986;7:31-8.
13 Cramer JA, Rosenbeck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201.
14 The Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study. II. Treatment: pimozide versus flupenthixol. Br J Psychiatry 1987;150:334-8.
15 Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Dutty JC. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. Br J Psychiatry 1985;146:469-74.
16 Strecher VJ, Rosenstock IM. The health belief model. In: Glanz K, Lewis FM, Rimer BK, eds. Health behaviour and health education. 2nd ed. San Francisco (CA): Jossey-Bass Publishers 1996:78-109.
17 Fishbein M, Ajzen I. Belief, attitude, intention, and behaviour: an introduction to theory and research. Reading (MA): Addison-Weseley 1975.
18 Di Matteo MR, Di Nicola DD. Achieving patient compliance: the psychology of the medical practitioner’s role. New York: Pergamon Press 1982.
19 Montano DE, Kaspryzyk D, Taplin HT. The theory of reasoned action and the theory of planned behaviour. In: Glanz K, Lewis FM, Rimer BK, eds. Health behaviour and health education. 2nd ed. San Francisco (CA): Jossey-Bass Publishers 1996:85-112.
20 Ajzen I. The theory of planned behavior. Organizazion of Behavioral Human Decisional Processes 1991:179-211.
21 Wang PS, Gilman ES, Guardino M, Christiana JM, Morselli PL, Mickelson K, et al. Initiation of and adherence to treatment for mental disorders. Med Care 2000;38:926-36.
22 Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-51.
23 Donohe G, Qwens N, O’Donnel C, Burke T, Moore L, Tobin A. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 2001;16:293-8.
24 Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000;61:5-11.
25 Baldessarini R. Enhancing treatment with psychotropic medication. Bull Menninger Clin 1994;58:224-41.
26 Parkes C, Brown G, Monck E. The general practitioner and the schizophrenic patient. B M J 1962;1:972-6.
27 Blackwell B. The drug defaulter. Clin Pharmacol Ther 1972;1:841-8.
28 Weiden PJ. Clinical non-recognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1991;286:1229-30.
29 Hoge S, Appelbaum P, Lawlor T. A prospective, multicenter study of patients' refusal of antipsychotic medication. Arch Gen Psychiatry 1990;47:949-56.
30 Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11-9.
31 Gerlach H, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994;55:107-9.
32 Day JC, Kinderman P, Bentall R. A comparison of patients’and prescribers’beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand 1998;97:93-7.
33 Henninger G, Dimascio A, Kelrman GL. Personality factors in variability of response to phenothiazines. Am J Psychiary 1965;121:1091-4.
34 Van Putten T, Mutalipassi LR, Malkin MD. Phenothiazine-induced decompensation. Arch Gen Psychiatry 1974;30:102-5.
35 Hogan TP, Awad AG, Eastwood R. Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia. Can J Psychiatry 1985;30:246-8.
36 Van Putten T, May PRA, Jenden DJ, Cho AK, Yale C. Plasma and saliva levels of chlorpromazine and subjective response. Am J Psychiatry 1980;137:1241-2.
37 Di Mascio A. Behavioral toxicity. In: Di Mascio A, Shader RI, eds. Clinical Handbook of Psychopharmacology. New York: Science House 1970:185-93.
38 Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Dis Nerv Syst 1976;37:191-6.
39 Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978;35:477-80.
40 Lipowski ZJ. The importance of body experience for psychiatry. Compr Psychiatry 1977;18:473-9.
41 Hogarty GE, Schooler NR, Ulrich RF, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients: Relapse analysis of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979;36:1283-94.
42 Van Putten T, May PR, Marder SR, Wittmann LA. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981;38:187-90.
43 Van Putten T, May PR, Marder SR. Response to antipsychotic medication: the doctor’s and the consumer’s view. Am J Psychiatry 1984;141:16-9.
44 May PRA, Van Putten T, Yale C. Predicting individual responses to drug treatment in schizophrenia: a test dose model. J Nerv Ment Dis 1976;162:177-83.
45 May PRA, Van Putten T, Jenden DJ, Yale C, Dixon WJ, Goldstein MJ. Prognosis in schizophrenia: individual differences in psychological response to a test dose of antipsychotic drug and their relationship to blood and saliva levels and treatment outcome. Compr Psychiatry 1981;22:147-52.
46 Van Putten T, May PRA, Marder SR. Subjective responses to thiothixene and chlorpromazine. Psychopharmacol Bull 1980;16:36-8.
47 Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D (2) binding ratios on SPECT images. Neuropsychopharmacol 2001;25:642-50.
48 Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischacker WW. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002;63:49-53.
49 Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-83.
50 Weiden P, Rapkin B, Mott T. Rating of medication influences scale (ROMI) in schizophrenia. Schizophr Bull 1994;20:297-307.
51 Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationship to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10:133-8.
52 Thompson K, Kulkami J, Sergejcw AA. Reliability and validity of a new medication adehrence rating scale (MARS) for the psychoses. Schizophr Res 2000;42:241-7.
53 Waserman J, Criollo M. Subjective experiences of clozapine treatment by patients with chronic schizophrenia. Psychiatr Serv 2000;51:666-8.
54 Awad A, Voruganti L. Quality of life and new antipsychotics in schizophrenia. Are patients better off? Int J Soc Psychiatry 1999;45:268-75.
55 Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsichotic adherence: is there differences between typical and atypical agents? Am J Psychiatry 2002;159:103-8.
56 Marder S. Facilitating compliance with antipsychotic medication. J Clin Psychiatry 1998;59:21-5.
57 Collaborative Group on Clinical Trial Evaluations. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. J Clin Psychiatry 1998;59:3-9.
58 Revicki D. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies. J Clin Psychiatry 1999;60:1,7-11.
59 Naber D, Holzbach R, Perris C. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 1992;160:54-9.
60 Lindström L. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988;77:524-9.
61 Aizenberg D, Modai I, Landa A, Gil-Ad I, Weizman A. Comparison of sexual disfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin Psychiatry 2001;62:541-4.
62 Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000;61:382-6.
63 Browne S, Garavan J, Gervin M. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J Nerv Ment Dis 1998;186:74-8.
64 Franz M, Lis S, Plüddemann K, Gallhofer B. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997;170:422-5.
65 Chouinard G, Jones B, Remington G. A Canadian multicenter placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
66 Marder S. The role of dosage and plasma levels in neuroleptic relapse prevention. Acta Psychiatr Scand 1994;89:25-7.
67 Green M, Marshall B, Wirshing W. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
68 Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 1996;41:35-40.
69 Mauskopf J, David K, Grainger D. Annual health outcomes and treatment cost for schizophrenia populations. J Clin Psychiatry 1999;60:14-9.
70 Rossi A, Arduini L, De Cataldo S, Stratta P. Gli aspetti soggettivi del trattamento con farmaci antipsicotici: studio di validazione della versione italiana della Drug Attitude Inventory (D.A.I.). Epidemiol Psichiatr Soc 2001;2:107-14.
71 Healey A, Knapp M, Astin J, Beecham J, Kemp R, Kirov J, et al. Cost-effectiveness evaluation of compliance therapy for people with psychosis. Br J Psychiatry 1998;172:420-4.
72 Kemp R, David A. Insight and adherence to treatment in psychotic disorders. Br J Hosp Med 1995;54:222-7.
73 Kemp R, David A. Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry 1996;169:444-50.
74 Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy i M r Med J 1996;312:345-9.
75 Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. Br J Psychiatry 1998;172:413-9.
76 Rossi A, Arduini L, Stratta P, Pallanti S. Subjective experience and subjective response to neuroleptics in schizophrenia. Compr Psychiatry 2000;41:446-9.